Nevirapine-based antiretroviral therapy is associated with lower plasma hepatitis C virus viral load among HIV/ hepatitis C Virus-Coinfected patients

7Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Objective: The aim of this study was to assess the relationship between the use of protease inhibitor (PI)-, nevirapine (NVP)- and efavirenz (EFV)-based antiretroviral therapy (ART) and plasma hepatitis C virus (HCV) viral load in a population of HIV/HCV-coinfected patients. Patients and Methods: We examined the relationship between the use of NVP-, PIs- and EFV-based ART and the plasma HCV viral load in HIV-infected patients without previous therapy against HCV. Results: The median HCV-RNA level (log10 IU/mL) was significantly lower in patients receiving NVP (5.7; Q1-Q3, 5.2-5.8) than in subjects treated with EFV (6.0; Q1-Q3, 5.5-6.5) and in individuals receiving PIs (6.1; Q1-Q3, 5.5-6.7) (p=0.016). Conclusions: HCV/HIV-coinfected individuals under NVP-based ART show lower plasma HCV-RNA levels than those receiving other regimens. © 2010 Mata RC, et al.

Cite

CITATION STYLE

APA

Mata, R. C., Mira, J. A., Rivero, A., López-Cortés, L. F., Torres-Tortosa, M., Merino, D., … Pineda, J. A. (2010). Nevirapine-based antiretroviral therapy is associated with lower plasma hepatitis C virus viral load among HIV/ hepatitis C Virus-Coinfected patients. Journal of AIDS and Clinical Research, 1(3). https://doi.org/10.4172/2155-6113.1000110

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free